Q BIOMED INC. STRENGTHENS ADVISORY BOARD

Company welcomes Dr. Susan E Quaggin, Dr. George Nikopoulos and Dr. MaryJane Rafii to its list of strategic advisors   NEW YORK, November 12, 2015 — Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce the addition of Mannin Research Inc. executives, Dr. Susan E Quaggin and Dr. George Nikopoulos […]

Read More

Vision Monday – Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement

Latest News Q BioMed Inc. and Mannin Research Inc. Sign Definitive License Agreement  By Staff Friday, November 6, 2015 12:18 AM NEW YORK—Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc., a biotechnology company leading the […]

Read More

GEN News – Q BioMed Licenses Mannin Platform for Vascular Drugs

GEN News Highlights Oct 30, 2015 Q BioMed Licenses Mannin Platform for Vascular Drugs Q BioMed said today it agreed to exclusively license—with an option to acquire—platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics. Mannin’s primary focus is developing a first-in-class therapeutic eye-drop for glaucoma in adults and […]

Read More

Q BioMed Inc. and Mannin Research Inc Sign Definitive License Agreement

Platform technology well positioned to be a First-In-Class molecule for the treatment of glaucoma as well as cystic kidney disease and others. NEW YORK, October 30, 2015 Q BioMed Inc. (OTC Pink: QBIO), a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets […]

Read More

Q BioMed Inc. Enters into Partnership with the Strategic and Scientific Advisory Firm Wombat Capital, Ltd.

Companies to collaborate on innovative Life Sciences asset discovery, evaluation and acquisition.   NEW YORK, October 13, 2015 — Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company, has entered into a strategic relationship with Wombat Capital, Ltd., a New York and Paris, France based strategic and scientific advisory firm.. This collaborative arrangement […]

Read More

Q BioMed Inc. is pleased to announce a Letter-Of-Intent to exclusively in-license and ultimately acquire the assets of Mannin Research Inc.

Technology asset well positioned to be a First-In-Class molecule for the treatment of Glaucoma, a leading cause of blindness in the US and around the world. NEW YORK, September 21, 2015 — Q BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company is pleased to announce a Letter of Intent to in-license and ultimately […]

Read More

Q BIOMED INC. PROVIDES CORPORATE UPDATE

Company Discusses Recent Corporate Actions and Advancement of Business Plan August 7, 2015, New York NY, Q BioMed Inc (OTC: QBIO) a biotechnology acceleration and development company is pleased to provide an update to shareholders and potential shareholders. Q BioMed Inc. has now completed its corporate and business restructuring. Over the last 3 months new […]

Social media & sharing icons powered by UltimatelySocial